CAS: 1432908-05-8
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | FRAX1036 REF: IN-DA009CMJCAS: 1432908-05-8 | % | 59.00 €~619.00 € | Tue 10 Dec 24 |
 | FRAX1036 REF: TM-T6839CAS: 1432908-05-8 | 97.66% - 99.95% | 51.00 €~500.00 € | Mon 16 Dec 24 |
 | FRAX1036 REF: 3D-HHC90805CAS: 1432908-05-8 | Min. 95% | To inquire | Tue 21 Jan 25 |
Ref: IN-DA009CMJ
| 1mg | 59.00 € | ||
| 5mg | 75.00 € | ||
| 10mg | 119.00 € | ||
| 50mg | 176.00 € | ||
| 100mg | 234.00 € | ||
| 250mg | 619.00 € |
Estimated delivery in United States, on Tuesday 10 Dec 2024
FRAX1036
CAS:1432908-05-8
FRAX-1036 is a effective and selective PAK1 inhibitor.
Formula:
C28H32ClN7O
Purity:
97.66% - 99.95%
Color and Shape:
Solid
Molecular weight:
518.05
Ref: TM-T6839
| 1mg | 51.00 € | ||
| 2mg | 68.00 € | ||
| 5mg | 96.00 € | ||
| 10mg | 118.00 € | ||
| 25mg | 207.00 € | ||
| 50mg | 346.00 € | ||
| 100mg | 500.00 € | ||
| 1mL*10mM (DMSO) | 96.00 € |
Estimated delivery in United States, on Monday 16 Dec 2024
FRAX1036
CAS:1432908-05-8
FRAX1036 is a new molecule which inhibits the cancer-promoting activity of epidermal growth factor (EGF). …
Formula:
C28H32ClN7O
Purity:
Min. 95%
Molecular weight:
518.05 g/mol
Ref: 3D-HHC90805
| 25mg | To inquire | ||
| 50mg | To inquire | ||
| 100mg | To inquire |
Estimated delivery in United States, on Tuesday 21 Jan 2025
